New Delhi, Oct 9 (PTI) Drug firm Lupin on Thursday announced the launch of a strategic partnership programme aimed at expanding the reach of a long-acting injectable platform developed by its subsidiary, Nanomi BV.

The platform, PrecisionSphere demonstrates efficacy and safety in drug delivery and is ready for commercial use, following the recent US Food and Drug Administration (USFDA) approval for the first product developed with this platform.

The company's partnership programme is designed to foster collaborations with companies looking to extend their product lifecycles, whether in development or already on the market, especially those that could benefit from longer-acting formulations, it said in a statement.

"With the validation of PrecisionSphere's capabilities and our proven tra

See Full Page